Improving conventional prognosticators in diffuse large B cell lymphoma using marker ratios

Kim Anh Lêcao; Colm Keane; Erica Han; Dipti Talaulikar; Maher Gandhi

Improving conventional prognosticators in diffuse large B cell lymphoma using marker ratios

Kim Anh Lêcao^*, Colm Keane, Erica Han, Dipti Talaulikar, Maher Gandhi

^*Corresponding author for this work

Research output: Contribution to journal › Conference article › peer-review

Abstract

Risk stratification for diffuse large B-cell lymphoma (DLBCL) is required as patients with disease may not be cured despite initial R-CHOP treatment. We investigated gene ratio tests to predict survival outcome of DLBCL patients based on the relationship between immune-effector and inhibitory (checkpoint) genes from nanoString™ nCounter in 158 paraffin-embedded DLBCL tissues. We assessed the predictive value of several possible gene ratios using a tree-based survival statistical model, and investigated the predictive value of those gene ratios in an independent R-CHOP treated cohorts of 233 patients. We showed that an immune ratio composed of CD4∗CD8∗:(CD163/CD68)∗PD-L1 was able to stratify overall survival better than single or combination of immune markers, distinguishing groups with disparate 4-year survivals (92% versus 47%). The immune ratio was independent of and added to the revised international prognostic index (R-IPI) and cell-of-origin (COO) and has potential implications for selection of patients for checkpoint-blockade within clinical trials.

Original language	English
Journal	CEUR Workshop Proceedings
Volume	1468
Publication status	Published - 2015
Event	Scientific Stream at Big Data in Health Analytics 2015, BigData 2015 - Sydney, Australia Duration: 20 Oct 2015 → 21 Oct 2015

Cite this

@article{41cada63831f4306a7fa49830345edbb,

title = "Improving conventional prognosticators in diffuse large B cell lymphoma using marker ratios",

abstract = "Risk stratification for diffuse large B-cell lymphoma (DLBCL) is required as patients with disease may not be cured despite initial R-CHOP treatment. We investigated gene ratio tests to predict survival outcome of DLBCL patients based on the relationship between immune-effector and inhibitory (checkpoint) genes from nanoString{\texttrademark} nCounter in 158 paraffin-embedded DLBCL tissues. We assessed the predictive value of several possible gene ratios using a tree-based survival statistical model, and investigated the predictive value of those gene ratios in an independent R-CHOP treated cohorts of 233 patients. We showed that an immune ratio composed of CD4∗CD8∗:(CD163/CD68)∗PD-L1 was able to stratify overall survival better than single or combination of immune markers, distinguishing groups with disparate 4-year survivals (92% versus 47%). The immune ratio was independent of and added to the revised international prognostic index (R-IPI) and cell-of-origin (COO) and has potential implications for selection of patients for checkpoint-blockade within clinical trials.",

keywords = "Gene expression, Survival analysis, Tumor associated macrophages",

author = "L{\^e}cao, {Kim Anh} and Colm Keane and Erica Han and Dipti Talaulikar and Maher Gandhi",

year = "2015",

language = "English",

volume = "1468",

journal = "CEUR Workshop Proceedings",

issn = "1613-0073",

publisher = "CEUR-WS",

note = "Scientific Stream at Big Data in Health Analytics 2015, BigData 2015 ; Conference date: 20-10-2015 Through 21-10-2015",

}

TY - JOUR

T1 - Improving conventional prognosticators in diffuse large B cell lymphoma using marker ratios

AU - Lêcao, Kim Anh

AU - Keane, Colm

AU - Han, Erica

AU - Talaulikar, Dipti

AU - Gandhi, Maher

PY - 2015

Y1 - 2015

N2 - Risk stratification for diffuse large B-cell lymphoma (DLBCL) is required as patients with disease may not be cured despite initial R-CHOP treatment. We investigated gene ratio tests to predict survival outcome of DLBCL patients based on the relationship between immune-effector and inhibitory (checkpoint) genes from nanoString™ nCounter in 158 paraffin-embedded DLBCL tissues. We assessed the predictive value of several possible gene ratios using a tree-based survival statistical model, and investigated the predictive value of those gene ratios in an independent R-CHOP treated cohorts of 233 patients. We showed that an immune ratio composed of CD4∗CD8∗:(CD163/CD68)∗PD-L1 was able to stratify overall survival better than single or combination of immune markers, distinguishing groups with disparate 4-year survivals (92% versus 47%). The immune ratio was independent of and added to the revised international prognostic index (R-IPI) and cell-of-origin (COO) and has potential implications for selection of patients for checkpoint-blockade within clinical trials.

AB - Risk stratification for diffuse large B-cell lymphoma (DLBCL) is required as patients with disease may not be cured despite initial R-CHOP treatment. We investigated gene ratio tests to predict survival outcome of DLBCL patients based on the relationship between immune-effector and inhibitory (checkpoint) genes from nanoString™ nCounter in 158 paraffin-embedded DLBCL tissues. We assessed the predictive value of several possible gene ratios using a tree-based survival statistical model, and investigated the predictive value of those gene ratios in an independent R-CHOP treated cohorts of 233 patients. We showed that an immune ratio composed of CD4∗CD8∗:(CD163/CD68)∗PD-L1 was able to stratify overall survival better than single or combination of immune markers, distinguishing groups with disparate 4-year survivals (92% versus 47%). The immune ratio was independent of and added to the revised international prognostic index (R-IPI) and cell-of-origin (COO) and has potential implications for selection of patients for checkpoint-blockade within clinical trials.

KW - Gene expression

KW - Survival analysis

KW - Tumor associated macrophages

UR - http://www.scopus.com/inward/record.url?scp=84954524050&partnerID=8YFLogxK

M3 - Conference article

AN - SCOPUS:84954524050

SN - 1613-0073

VL - 1468

JO - CEUR Workshop Proceedings

JF - CEUR Workshop Proceedings

T2 - Scientific Stream at Big Data in Health Analytics 2015, BigData 2015

Y2 - 20 October 2015 through 21 October 2015

ER -

Improving conventional prognosticators in diffuse large B cell lymphoma using marker ratios

Abstract

Other files and links

Fingerprint

Cite this